Subtype
Lung Neuroendocrine Carcinoma
CI-CAN-00003107Explore in graph →
389 active trials6 approved drugs6 evidence items
- NCIt
- C45569
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003107Explore in graph →
Clinical trials
1,113 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (159)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01266018 | Study of ADI-PEG 20 in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer | terminated | Phase 2 | 22 | Ludwig Institute for Cancer ResearchOTHER | 5 | Oct 25, 2022 | clinicaltrials |
| NCT02359019 | MK-3475 as Maintenance Therapy in Extensive Stage SCLC | completed | Phase 2 | 45 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Oct 14, 2022 | clinicaltrials |
| NCT05484583 | Durvalumab Combined With Consolidation Radiotherapy After First-line Treatment in Extensive Stage Small Cell Lung Cancer With Oligometastases | not yet recruiting | Phase 2 | 58 | Affiliated Cancer Hospital & Institute of Guangzhou Medical UniversityOTHER | 0 | Aug 5, 2022 | clinicaltrials |
| NCT05483543 | Pamiparib for Consolidation Treatment of Unprogressed LS-SCLC After Concurrent Chemoradiotherapy | unknown | Phase 2 | 44 | Fudan UniversityOTHER | 1 | Aug 2, 2022 | clinicaltrials |
| NCT02945852 | Apatinib for Extensive Stage Small Cell Lung Cancer After Second/Third Line Chemotherapy. | completed | Phase 2 | 40 | Fan Yun, MDOTHER | 1 | Jul 19, 2022 | clinicaltrials |
| NCT04210037 | Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 28 | Ascentage Pharma Group Inc.INDUSTRY | 2 | Jul 12, 2022 | clinicaltrials |
| NCT04636762 | A Study of Concurrent Chemoradiation With Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC) | completed | Phase 2 | 40 | Second Xiangya Hospital of Central South UniversityOTHER | 1 | Jun 14, 2022 | clinicaltrials |
| NCT03365791 | PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies | completed | Phase 2 | 76 | Novartis PharmaceuticalsINDUSTRY | 1 | May 27, 2022 | clinicaltrials |
| NCT05354700 | A Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy in Patients With Extensive Small Cell Lung Cancer | unknown | Phase 2 | 20 | Shanghai Henlius BiotechINDUSTRY | 1 | May 4, 2022 | clinicaltrials |
| NCT05162196 | The Efficacy and Safety of Radiotherapy Plus Niraparib and Toripalimab in Patients With Recurrent Small Cell Lung Cancer | unknown | Phase 2 | 57 | Wuhan UniversityOTHER | 0 | May 2, 2022 | clinicaltrials |
| NCT04841538 | A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Malignant Thoracic Tumors | withdrawn | Phase 1 / Phase 2 | 0 | Elpiscience Biopharma, Ltd.INDUSTRY | 0 | Apr 29, 2022 | clinicaltrials |
| NCT01441349 | Irinotecan/Cisplatin With or Without Simvastatin in Chemo-naive Patients With Extensive Disease-small Cell Lung Cancer | unknown | Phase 2 | 192 | National Cancer Center, KoreaOTHER_GOV | 1 | Apr 6, 2022 | clinicaltrials |
| NCT05299255 | Utidelone in Third-line and Above Treatment of Small Cell Lung Cancer | unknown | Phase 2 | 40 | Henan Cancer HospitalOTHER_GOV | 1 | Mar 28, 2022 | clinicaltrials |
| NCT04525391 | AZD2811 and Durvalumab (MEDI4736) Combination Therapy in Relapsed Small Cell Lung Cancer(SUKSES-N5) | terminated | Phase 2 | 4 | Se-Hoon LeeOTHER | 1 | Feb 25, 2022 | clinicaltrials |
| NCT05245994 | An Open Label, Multicenter Phase 2 Study of Durvalumab (MEDI4736) + Olaparib as Maintenance Therapy in Chinese | unknown | Phase 2 | 60 | Li Zhang, MDOTHER | 1 | Feb 18, 2022 | clinicaltrials |
| NCT03221400 | PEN-866 in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 340 | Tarveda TherapeuticsINDUSTRY | 1 | Feb 17, 2022 | clinicaltrials |
| NCT01935336 | Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers | completed | Phase 2 | 171 | University of Colorado, DenverOTHER | 1 | Feb 11, 2022 | clinicaltrials |
| NCT02446704 | Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy | unknown | Phase 1 / Phase 2 | 66 | Zofia PiotrowskaOTHER | 1 | Feb 7, 2022 | clinicaltrials |
| NCT05158491 | Safety, Tolerability and Preliminary Efficacy of JK1201I in Patients With SCLC | unknown | Phase 1 / Phase 2 | 63 | JenKem Technology Co., Ltd.INDUSTRY | 1 | Jan 5, 2022 | clinicaltrials |
| NCT02936323 | PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers | completed | Phase 1 / Phase 2 | 89 | Tarveda TherapeuticsINDUSTRY | 2 | Dec 14, 2021 | clinicaltrials |
| NCT04901754 | Camrelizumab Plus Apatinib as Maintenance Therapy in Extensive-stage Small-cell Lung Cancer(CAMERA) | unknown | Phase 2 | 38 | Henan Cancer HospitalOTHER_GOV | 1 | Dec 8, 2021 | clinicaltrials |
| NCT00695292 | Irinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung Cancer | completed | Phase 2 | 37 | SCRI Development Innovations, LLCOTHER | 1 | Nov 22, 2021 | clinicaltrials |
| NCT02934503 | Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung Cancer (SCLC) | terminated | Phase 2 | 5 | NYU Langone HealthOTHER | 1 | Nov 16, 2021 | clinicaltrials |
| NCT03371979 | Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 68 | Aeglea BiotherapeuticsINDUSTRY | 2 | Nov 4, 2021 | clinicaltrials |
| NCT05034133 | Durvalumab With Chemotherapy Followed by Sequential Radiotherapy for Limited Stage Small Cell Lung Cancer | unknown | Phase 2 | 20 | Beijing Haidian HospitalOTHER | 1 | Sep 5, 2021 | clinicaltrials |
| NCT01631552 | Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer | completed | Phase 1 / Phase 2 | 515 | Gilead SciencesINDUSTRY | 1 | Aug 12, 2021 | clinicaltrials |
| NCT04985201 | Combined Simvastatin and Irinotecan in Treating ES-SCLC Patients Relapsed From 1st Chemotherapy | unknown | Phase 2 | 40 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Aug 9, 2021 | clinicaltrials |
| NCT02674568 | Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer(TRINITY) | completed | Phase 2 | 342 | AbbVieINDUSTRY | 0 | Jul 30, 2021 | clinicaltrials |
| NCT04698941 | Combined Simvastatin and Albumin Paclitaxel in Treating ES-SCLC Patients Relapsed From 1st Chemotherapy | unknown | Phase 2 | 40 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Jul 29, 2021 | clinicaltrials |
| NCT03092934 | A Study of AK-01 (LY3295668) in Solid Tumors | completed | Phase 1 / Phase 2 | 13 | Eli Lilly and CompanyINDUSTRY | 1 | Jul 2, 2021 | clinicaltrials |
| NCT02701400 | Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer | completed | Phase 2 | 18 | Emory UniversityOTHER | 1 | Jun 22, 2021 | clinicaltrials |
| NCT04933175 | Fluzopalil in Combination With Anlotinib for Extensive Small-cell Lung Cancer | unknown | Phase 2 | 50 | Liu ZhenhuaOTHER | 1 | Jun 21, 2021 | clinicaltrials |
| NCT04890795 | A Phase Ib / IIA Study of AL8326 in Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 237 | Advenchen Laboratories Nanjing Ltd.INDUSTRY | 1 | May 18, 2021 | clinicaltrials |
| NCT02593019 | Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients | completed | Phase 2 | 24 | Samsung Medical CenterOTHER | 1 | Mar 19, 2021 | clinicaltrials |
| NCT02722369 | STUDY 15 - Comparing Gemcitabine/Carboplatin and Hydroxychloroquine Versus Carboplatin/Etoposide Therapy Alone in Small Cell Lung Cancer (SCLC) | terminated | Phase 2 | 72 | University College, LondonOTHER | 1 | Mar 18, 2021 | clinicaltrials |
| NCT03325816 | Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 9 | Georgetown UniversityOTHER | 1 | Mar 16, 2021 | clinicaltrials |
| NCT04790539 | a Study of SHR1210 in Combination With Paclitaxel-albumin and Carboplatin in Extensive Stage Small Cell Lung Cancer | unknown | Phase 2 | 71 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 0 | Mar 10, 2021 | clinicaltrials |
| NCT04543916 | Venetoclax and Irinotecan in Relapsed/Refractory SCLC | withdrawn | Phase 1 / Phase 2 | 0 | Virginia Commonwealth UniversityOTHER | 0 | Mar 3, 2021 | clinicaltrials |
| NCT03009682 | Olaparib Monotherapy in Relapsed Small Cell Lung Cancer Patients With HR Pathway Gene Mutations Not Limited to BRCA 1/2 Mutations, ATM Deficiency or MRE11A Mutations(SUKSES-B) | completed | Phase 2 | 15 | Samsung Medical CenterOTHER | 1 | Feb 18, 2021 | clinicaltrials |
| NCT03428607 | Study of AZD6738 and Olaparib Combination Therapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N2] | completed | Phase 2 | 26 | Samsung Medical CenterOTHER | 1 | Feb 18, 2021 | clinicaltrials |
| NCT04757779 | A Single-arm, Phase Ⅱ Clinical Trial of Anlotinib Hydrochloride Combined With Irinotecan or Docetaxel for Second Line Treatment of Nonsensitive Relapsed Small-cell Lung Cancer | unknown | Phase 2 | 40 | First People's Hospital of HangzhouOTHER | 1 | Feb 17, 2021 | clinicaltrials |
| NCT03059667 | Immunotherapy as Second-line in Patient With Small Cell Lung Cancer | completed | Phase 2 | 73 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Feb 10, 2021 | clinicaltrials |
| NCT04740021 | Study of LP002 in Combination With Chemotherapy for Patients With Extensive Stage Small Cell Lung Cancer | unknown | Phase 2 | 46 | Taizhou HoudeAoke Biomedical Co., Ltd.INDUSTRY | 1 | Feb 5, 2021 | clinicaltrials |
| NCT02171325 | Study of Different Doses of Irinotecan and Cisplatin for First-line Extensive-stage Small-cell Lung Cancer Treatment | unknown | Phase 2 | 54 | Guangdong Association of Clinical TrialsOTHER | 1 | Feb 3, 2021 | clinicaltrials |
| NCT02337712 | Once-daily Simultaneous Modulated Accelerated Thoracic Radiotherapy in Limited Small-cell Lung Cancer | unknown | Phase 2 | 198 | Sun Yat-sen UniversityOTHER | 1 | Jan 27, 2021 | clinicaltrials |
| NCT03901378 | Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma | withdrawn | Phase 2 | 0 | Ochsner Health SystemOTHER | 1 | Jan 25, 2021 | clinicaltrials |
| NCT04696939 | Combined Atezolizumab and Chemotherapy (Carboplatin Plus Etoposide) in Neoadjuvant Treating Limited-Stage Small Cell Lung Cancer Patients | unknown | Phase 2 | 100 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Jan 6, 2021 | clinicaltrials |
| NCT04683198 | Camrelizumab Combined With Apatinib ,Carboplatin and Etoposide in Participants With ES-SCLC | unknown | Phase 2 | 69 | Chinese Academy of Medical SciencesOTHER | 0 | Dec 24, 2020 | clinicaltrials |
| NCT04684017 | Anlotinib Plus Etoposide and Carboplatin as First-line Treatment for Extensive-stage Small Cell Lung Cancer | unknown | Phase 2 | 29 | Shanghai Chest HospitalOTHER | 1 | Dec 24, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Oct 25, 2022source: clinicaltrials